Efficacy and safety of neoadjuvant treatment with PD-1 inhibitor in locally advanced head and neck squamous cell carcinoma
Shaowei Xu, Hongxin Zheng, Xiaoqi Liao, Manyu Jiang, Hanwei Peng, Muyuan Liu · 2026
Read Efficacy and safety of neoadjuvant treatment with PD-1 inhibitor in locally advanced head and neck squamous cell carcinoma by Shaowei Xu, Hongxin Zheng, Xiaoqi Liao, Manyu Jiang, Hanwei Peng, Muyuan Liu (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13553248.txt.
Description
Shaowei Xu and co-authors looked back in 2026 at immune drug treatment given before surgery for advanced head and neck cancer. Standard care has uneven results, with return, resistance, and side effects all common. Immune drugs have helped when this cancer returns or spreads, but early use is less studied.
Patients at one cancer hospital from 2020 to 2024 got either immune drug plus standard drugs or standard drugs alone. Scan-based results did not differ clearly between groups. The immune group, though, had more tumor shrinkage in tissue and more cases with no tumor left. Survival was also better, and safety was fair. Larger planned trials are needed, the authors say.
Catalog record
| CREATOR | Shaowei Xu, Hongxin Zheng, Xiaoqi Liao, Manyu Jiang, Hanwei Peng, Muyuan Liu |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 36 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |